



THE JOURNAL OF
CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study

Author(s): Leslie Citrome, MD, MPH; Marina Komaroff, DrPH; Brittney Starling, PharmD; Sandeep Byreddy, MS; Takaaki Terahara, PhD; and Masami Hasebe, MPharm

DOI Number: <https://doi.org/10.4088/JCP.21m14355>

List of Supplementary Material for the article

1. [Table 1](#) Change from Baseline to Week 6 for the PANSS Hostility Item (P7) in Patients with Baseline Hostility Score >1 (Full Analysis Set)
2. [Table 2](#) Change from Baseline in PANSS-EC Adjusted for Country (Full Analysis Set)
3. [Table 3](#) Change from Baseline in PANSS-EC Adjusted for Country in Patients with Baseline Hostility Score >1 (Full Analysis Set)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1. Change from Baseline to Week 6 for the PANSS Hostility Item (P7) in Patients with Baseline Hostility Score >1 (Full Analysis Set)

	HP-3070 7.6 mg/24h (n=151)	HP-3070 3.8 mg/24h (n=147)	Placebo (n=144)	Difference from Placebo for HP-3070 7.6 mg/24h	Difference from Placebo for HP-3070 3.8 mg/24h
Unadjusted					
LS mean (estimated)	-0.9	-0.8	-0.5	-0.4	-0.3
SE	0.08	0.08	0.08	0.11	0.11
95% CI	-1.02 to -0.71	-0.99 to -0.67	-0.65 to -0.32	-0.60 to -0.16	-0.57 to -0.12
<i>P</i> value	<.001	<.001	<.001	<.001	.003
Adjusted for PANSS-Positive Symptoms^a					
LS mean (estimated)	-0.7	-0.6	-0.4	-0.3	-0.2
SE	0.07	0.07	0.07	0.10	0.10
95% CI	-0.83 to -0.55	-0.77 to -0.49	-0.58 to -0.30	-0.44 to -0.06	-0.39 to -0.00
<i>P</i> value	<.001	<.001	<.001	.011	.049
Adjusted for PANSS-Positive Symptoms^a & AE Somnolence or Akathisia					
LS mean (estimated)	-0.7	-0.7	-0.5	-0.2	-0.2
SE	0.09	0.09	0.09	0.10	0.10
95% CI	-0.91 to -0.56	-0.85 to -0.50	-0.66 to -0.31	-0.44 to -0.06	-0.39 to 0.00
<i>P</i> value	<.001	<.001	<.001	.012	.052

^aPANSS-Positive symptoms of schizophrenia is a sum of the P1 P2, P3, P5, P6, and G9 items.

Abbreviations: AE = adverse event, LS = least-squares, SE = standard error, PANSS = Positive and Negative Syndrome Scale.

Supplementary Table 2. Change from Baseline in PANSS-EC Adjusted for Country (Full Analysis Set)

		HP-3070 7.6 mg/24h (n=203)	HP-3070 3.8 mg/24h (n=201)	Placebo (n=203)	Difference from Placebo for HP-3070 7.6 mg/24h	Difference from Placebo for HP-3070 3.8 mg/24h
Week 1	LS mean (estimated)	-1.1	-0.9	-0.7	-0.4	-0.2
	SE	0.175	0.175	0.176	0.240	0.240
	95% CI	-1.43 to -0.75	-1.26 to -0.57	-1.06 to -0.37	-0.85 to 0.09	-0.67 to 0.27
	<i>P</i> value				.116	.412
Week 2	LS mean (estimated)	-1.9	-1.7	-1.2	-0.7	-0.6
	SE	0.211	0.210	0.211	0.292	0.291
	95% CI	-2.34 to -1.51	-2.16 to -1.33	-1.59 to -0.77	-1.32 to -0.17	-1.14 to 0.01
	<i>P</i> value				.011	.054
Week 3	LS mean (estimated)	-2.3	-2.2	-1.5	-0.7	-0.6
	SE	0.220	0.220	0.221	0.305	0.306
	95% CI	-2.69 to -1.83	-2.61 to -1.75	-1.98 to -1.11	-1.31 to -0.11	-1.23 to -0.03
	<i>P</i> value				.020	.039
Week 4	LS mean (estimated)	-2.5	-2.8	-1.8	-0.6	-1.0
	SE	0.240	0.240	0.241	0.335	0.335
	95% CI	-2.94 to -2.00	-3.28 to -2.34	-2.30 to -1.35	-1.30 to 0.01	-1.65 to -0.33
	<i>P</i> value				.054	.003
Week 5	LS mean (estimated)	-2.8	-3.1	-1.9	-0.9	-1.2

		HP-3070 7.6 mg/24h (n=203)	HP-3070 3.8 mg/24h (n=201)	Placebo (n=203)	Difference from Placebo for HP-3070 7.6 mg/24h	Difference from Placebo for HP-3070 3.8 mg/24h
	SE	0.253	0.252	0.254	0.354	0.353
	95% CI	-3.30 to -2.30	-3.64 to -2.65	-2.40 to -1.40	-1.60 to -0.21	-1.94 to -0.55
	<i>P</i> value				.011	<.001
Week 6	LS mean (estimated)	-3.2	-3.3	-2.0	-1.1	-1.3
	SE	0.266	0.264	0.266	0.371	0.370
	95% CI	-3.71 to -2.67	-3.85 to -2.81	-2.57 to -1.53	-1.87 to -0.41	-2.01 to -0.55
	<i>P</i> value				.002	<.001

Abbreviations: LS = least-squares, SE = standard error, PANSS-EC = Positive and Negative Syndrome Scale-Excited Component.

Supplementary Table 3. Change from Baseline in PANSS-EC Adjusted for Country in Patients with Baseline Hostility Score >1 (Full Analysis Set)

		HP-3070 7.6 mg/24h (n=151)	HP-3070 3.8 mg/24h (n=149)	Placebo (n=147)	Difference from Placebo for HP-3070 7.6 mg/24h	Difference from Placebo for HP-3070 3.8 mg/24h
Week 1	LS mean (estimated)	-1.1	-0.9	-0.7	-0.4	-0.2
	SE	0.175	0.175	0.176	0.240	0.240
	95% CI	-1.43 to -0.75	-1.26 to -0.57	-1.06 to -0.37	-0.85 to 0.09	-0.67 to 0.27
	<i>P</i> value				.116	.412
Week 2	LS mean (estimated)	-2.3	-2.1	-1.3	-1.0	-0.8
	SE	0.249	0.251	0.256	0.351	0.351
	95% CI	-2.82 to -1.84	-2.58 to -1.59	-1.80 to -0.80	-1.72 to -0.35	-1.48 to -0.09
	<i>P</i> value				.003	.026
Week 3	LS mean (estimated)	-2.7	-2.5	-1.8	-0.9	-0.7
	SE	0.259	0.263	0.268	0.366	0.369
	95% CI	-3.19 to -2.17	-3.04 to -2.01	-2.33 to -1.28	-1.59 to -0.16	-1.44 to 0.01
	<i>P</i> value				.017	.052
Week 4	LS mean (estimated)	-3.0	-3.3	-2.1	-0.9	-1.2
	SE	0.283	0.289	0.293	0.402	0.406
	95% CI	-3.57 to -2.46	-3.85 to -2.71	-2.66 to -1.50	-1.72 to -0.14	-2.00 to -0.40
	<i>P</i> value				.021	.003
Week 5	LS mean (estimated)	-3.2	-3.7	-2.2	-1.1	-1.5

		HP-3070 7.6 mg/24h (n=151)	HP-3070 3.8 mg/24h (n=149)	Placebo (n=147)	Difference from Placebo for HP-3070 7.6 mg/24h	Difference from Placebo for HP-3070 3.8 mg/24h
	SE	0.304	0.309	0.314	0.432	0.436
	95% CI	-3.85 to -2.65	-4.26 to -3.05	-2.80 to -1.57	-1.92 to -0.22	-2.33 to -0.62
	<i>P</i> value				.014	<.001
Week 6	LS mean (estimated)	-3.6	-3.8	-2.6	-1.0	-1.2
	SE	0.320	0.325	0.330	0.454	0.457
	95% CI	-4.22 to -2.96	-4.40 to -3.12	-3.23 to -1.93	-1.91 to -0.12	-2.08 to -0.28
	<i>P</i> value				.026	0.010

Abbreviations: LS, least-squares; SE, standard error; PANSS-EC, Positive and Negative Syndrome Scale-Excited Component.